NR AFOS
AU Hornsey,V.S.; Drummond,O.; Young,D.; Docherty,A.; Prowse,C.V.
TI A potentially improved approach to methylene blue virus inactivation of plasma: the Maco Pharma Maco-Tronic system.
QU Transfusion Medicine 2001 Feb; 11(1): 31-6
PT journal article
AB Plasma was subjected to methylene blue (MB) photochemical virus inactivation using the Maco Pharma Maco-Tronic system which allows three units to be illuminated together, thus reducing processing time. The plasma bag system used incorporates an integral membrane plasma filter and a dry MB pill which dissolves in the plasma to give a 1-microM concentration. There is computer-controlled processing and datalogging. In an assessment of 10 pools of Group A plasma, the losses of coagulation factors, following MB/light treatment, were 23% fibrinogen, 10% FV, 26% FVIII, 11% FIX and 13% FXI. Group O, Group B and Group AB plasmas were not tested. Von Willebrand factor (vWf) multimers showed no substantial change when treated with MB, and no losses were seen for antithrombin III (ATIII), protein C and vWf:Ag. Measurements of C3a, C5a, prothrombin fragment 1+2 and FXIIa indicated that there was no activation as a result of filtration.
MH Antithrombin III/analysis; Blood/*virology; Blood Coagulation Factors/analysis; Blood Transfusion/standards; Complement 3a/analysis; Complement 5a/analysis; Factor XIIa/analysis; Fibrinogen/analysis; Human; Leukocyte Count; Light; Methylene Blue/*pharmacology; Platelet Count; PrPc Proteins/blood; Support, Non-U.S. Gov't; Viruses/*drug effects/growth & development
AD Transfusion Service, National Science Laboratory, Edinburgh, UK. valerie.hornsey@snbts.csa.scot.nhs.uk
SP englisch
PO England